Better treatments that cost more: the dilemma

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.

Breast cancer research and treatment·2020

Urinary stress incontinence and other maternal outcomes 2 years after caesarean or vaginal birth for twin pregnancy: a multicentre randomised trial.

BJOG : an international journal of obstetrics and gynaecology·2018

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

Current oncology (Toronto, Ont.)·2017

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.

Current oncology (Toronto, Ont.)·2016

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.

BMC cancer·2016

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Gynecologic oncology·2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Gynecologic oncology·2026

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Gynecologic oncology·2026

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Gynecologic oncology·2026

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Gynecologic oncology·2026

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Gynecologic oncology·2026

Assessment of Knowledge, Attitudes, and Practices around Cervical Cancer Screening in the Gulu District of Northern Uganda: A cross-sectional study.

International journal for quality in health care : journal of the International Society for Quality in Health Care·2026

HPV Knowledge, Anxiety and Vaccine Acceptance Among Adults in Saudi Arabia: A Cross-Sectional Study.

Public health nursing (Boston, Mass.)·2026

Implementing early warning systems for sepsis recognition in African healthcare settings: an Angolan perspective.

African journal of emergency medicine : Revue africaine de la medecine d'urgence·2026

Health in nationally determined contributions: a policy analysis of 191 countries.

Environment international·2026

Tobacco control without cessation? Policy gaps in cessation services in Bangladesh.

Public health in practice (Oxford, England)·2026

PHGDH: metabolic enzyme or signaling hub? From broad-spectrum inhibition toward context-adapted therapeutic targeting.

Biochemical pharmacology·2026

Related Experiment Videos

Better treatments that cost more: the dilemma

Related Concept Videos

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.

Urinary stress incontinence and other maternal outcomes 2 years after caesarean or vaginal birth for twin pregnancy: a multicentre randomised trial.

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Assessment of Knowledge, Attitudes, and Practices around Cervical Cancer Screening in the Gulu District of Northern Uganda: A cross-sectional study.

HPV Knowledge, Anxiety and Vaccine Acceptance Among Adults in Saudi Arabia: A Cross-Sectional Study.

Implementing early warning systems for sepsis recognition in African healthcare settings: an Angolan perspective.

Health in nationally determined contributions: a policy analysis of 191 countries.

Tobacco control without cessation? Policy gaps in cessation services in Bangladesh.

PHGDH: metabolic enzyme or signaling hub? From broad-spectrum inhibition toward context-adapted therapeutic targeting.

Related Experiment Videos

Better treatments that cost more: the dilemma

Related Concept Videos

Related Articles